Skip to main content
FOR HEALTHCARE PROFESSIONALS ONLY
Sanofi branded clouded background image

Latest Articles

Diagnosing autoimmune T1D: When and How?

People with autoimmune type 1 diabetes (autoimmune T1D) often present with acute symptoms of diabetes, markedly elevated blood glucose levels and 25–50% are diagnosed with life-threatening diabetic ketoacidosis (DKA).1 However, autoimmune T1D is a progressive disease that progresses through distinct stages before clinical symptoms are observed.2,3 Early T1D detection is possible; by identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.4

Learn more
girls raising hand

Screening for autoimmune type 1 diabetes using autoantibodies

Early screening for type 1 diabetes autoantibodies enables the identification of individuals at risk before symptoms appear, allowing for timely intervention and disease management.1 Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (autoimmune T1D) development.2 The number of detectable autoantibodies through screening correlates with the risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3

Learn more

The role of antibodies and autoantibodies in autoimmune type 1 diabetes

B cells produce autoantibodies against pancreatic islet cells months and even up to years before the onset of clinically relevant symptoms of autoimmune type 1 diabetes (autoimmune T1D), providing an opportunity for early detection and potential prevention of autoimmune T1D onset.1-2 These type 1 diabetes (T1D) autoantibodies serve as important biomarkers for the development and progression of autoimmune T1D.1

Learn more